Big Pharma's Manufacturing Blueprint for the Future - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Pharma's Manufacturing Blueprint for the Future
The pharmaceutical majors continue rationalizing manufacturing capacity in established markets as they forge their manufacturing networks in biologics and emerging markets.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 40-47

Roche. In November 2010, Roche announced a companywide restructuring plan that is designed to result in annual cost savings of CHF 2.4 billion ($3.0 billion). Implementation, which is scheduled for 2011 and 2012, includes plans for reducing its workforce by 4800 positions worldwide. Most of the planned job reductions will occur in Roche's pharmaceuticals division, particularly in global sales and marketing organization and in manufacturing.

To further improve capacity utilization within its global manufacturing network, some technical operations activities will be reorganized in California, the US, Mannheim, Germany, and various other sites. In addition, Roche intends to seek buyers for its sites in Florence, South Carolina, and Boulder, Colorado. In its diagnostics group, Roche plans to close its manufacturing site in Graz, Austria, and transfer development and manufacturing activities relating to blood gas diagnostics to Rotkreuz, Switzerland, where the division's professional diagnostics unit has its global headquarters. Diagnostics chemical manufacturing and analytical services are expected to be discontinued in Mannheim, Germany, and transferred to Penzberg, Germany.

Roche will discontinue certain activities in research and early development. These include RNA interference research in Kulmbach, Germany, Nutley, New Jersey, and Madison, Wisconsin. In addition, plans also include reorganizing certain internal functions to free up resources for upcoming Phase II studies of new molecular entities.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here